文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于受限紊乱原理的第二代人工智能数字医用大麻系统:真实世界数据分析

A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis.

作者信息

Hurvitz Noa, Lehman Hillel, Hershkovitz Yoav, Kolben Yotam, Jamil Khurram, Agus Samuel, Berg Marc, Aamar Suhail, Ilan Yaron

机构信息

Department of Medicine, Hadassah Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Oberon Sciences and Area 9 Innovation, Coppnehagen, Denmark.

出版信息

J Public Health Res. 2025 Jun 9;14(2):22799036251337640. doi: 10.1177/22799036251337640. eCollection 2025 Apr.


DOI:10.1177/22799036251337640
PMID:40496893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12149626/
Abstract

INTRODUCTION: Adhering to treatment plans can be challenging for medical cannabis patients. According to the constrained-disorder principle (CDP), biological systems are defined by their degree of variability. CDP-based second-generation artificial intelligence (AI) systems use personalized variability signatures to improve chronic medication response. AIM: We retrospectively analyzed real-world data regarding chronic pain patients using the second generation of artificial intelligence systems to improve adherence to medical cannabis and increase its effectiveness. DESIGN AND METHODS: A retrospective analysis of real-world data of 27 patients using prescribed medical cannabis for chronic pain was conducted. Patients received treatment according to a regimen provided by the CDP-based second-generation AI Altus Care™ app that managed the product's dosage and administration times. The app offers a therapeutic regimen by varying dosages and administration times within predefined ranges. We included 16 patients who participated for more than a week. We assessed adherence to therapy and clinical response in real life based on pain scale measurements. RESULTS: The patients were followed up for 64 days (30-189). Second-generation, AI-based, personalized regimens had a high engagement rate and adherence. 50% of patients showed a high compliance rate. Chronic pain improved in patients who reported their pain score. SUMMARY: This preliminary real-world data analysis suggests that an algorithm-based approach using a second-generation AI system may enhance the adherence to and clinical effectiveness of medical cannabis. These findings require confirmation through prospective controlled studies.

摘要

引言:对于医用大麻患者而言,坚持治疗方案可能具有挑战性。根据受限-紊乱原则(CDP),生物系统由其变异性程度来定义。基于CDP的第二代人工智能(AI)系统使用个性化变异性特征来改善慢性药物治疗反应。 目的:我们使用第二代人工智能系统对慢性疼痛患者的真实世界数据进行回顾性分析,以提高对医用大麻的依从性并增强其疗效。 设计与方法:对27名使用处方医用大麻治疗慢性疼痛的患者的真实世界数据进行回顾性分析。患者根据基于CDP的第二代AI Altus Care™应用程序提供的方案接受治疗,该应用程序管理产品的剂量和给药时间。该应用程序通过在预定义范围内改变剂量和给药时间来提供治疗方案。我们纳入了16名参与超过一周的患者。我们根据疼痛量表测量评估现实生活中的治疗依从性和临床反应。 结果:患者随访了64天(30 - 189天)。基于第二代AI的个性化方案具有较高的参与率和依从性。50%的患者显示出高依从率。报告疼痛评分的患者慢性疼痛有所改善。 总结:这项初步的真实世界数据分析表明,使用第二代AI系统的基于算法的方法可能会提高医用大麻的依从性和临床疗效。这些发现需要通过前瞻性对照研究来证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7137/12149626/806c9bd46cc0/10.1177_22799036251337640-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7137/12149626/b28f4484671d/10.1177_22799036251337640-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7137/12149626/806c9bd46cc0/10.1177_22799036251337640-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7137/12149626/b28f4484671d/10.1177_22799036251337640-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7137/12149626/806c9bd46cc0/10.1177_22799036251337640-fig2.jpg

相似文献

[1]
A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis.

J Public Health Res. 2025-6-9

[2]
Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response.

Front Med (Lausanne). 2022-1-24

[3]
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.

Front Oncol. 2024-7-30

[4]
A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial.

Biomed Pharmacother. 2023-5

[5]
The Co-Piloting Model for Using Artificial Intelligence Systems in Medicine: Implementing the Constrained-Disorder-Principle-Based Second-Generation System.

Bioengineering (Basel). 2024-11-3

[6]
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy.

J Clin Med. 2024-6-5

[7]
The Constrained Disorder Principle Overcomes the Challenges of Methods for Assessing Uncertainty in Biological Systems.

J Pers Med. 2024-12-28

[8]
The Constrained-Disorder Principle Assists in Overcoming Significant Challenges in Digital Health: Moving from "Nice to Have" to Mandatory Systems.

Clin Pract. 2023-8-20

[9]
Exploring the Effect of an 8-Week AI-Composed Exercise Program on Pain Intensity and Well-Being in Patients With Spinal Pain: Retrospective Cohort Analysis.

JMIR Form Res. 2025-2-18

[10]
Prescription of Controlled Substances: Benefits and Risks

2025-1

本文引用的文献

[1]
The Constrained Disorder Principle Overcomes the Challenges of Methods for Assessing Uncertainty in Biological Systems.

J Pers Med. 2024-12-28

[2]
The constrained-disorder principle defines the functions of systems in nature.

Front Netw Physiol. 2024-12-18

[3]
The Co-Piloting Model for Using Artificial Intelligence Systems in Medicine: Implementing the Constrained-Disorder-Principle-Based Second-Generation System.

Bioengineering (Basel). 2024-11-3

[4]
Using the Constrained Disorder Principle to Navigate Uncertainties in Biology and Medicine: Refining Fuzzy Algorithms.

Biology (Basel). 2024-10-16

[5]
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders.

Immunotargets Ther. 2024-10-14

[6]
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.

Front Oncol. 2024-7-30

[7]
Free Will as Defined by the Constrained Disorder Principle: a Restricted, Mandatory, Personalized, Regulated Process for Decision-Making.

Integr Psychol Behav Sci. 2024-12

[8]
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy.

J Clin Med. 2024-6-5

[9]
The Constrained Disorder Principle May Account for Consciousness.

Brain Sci. 2024-2-23

[10]
Special Issue "Computer-Aided Drug Discovery and Treatment".

Int J Mol Sci. 2024-2-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索